NMN (Nicotinamide Mononucleotide)
NMN is a direct NAD+ precursor nucleotide that raises cellular NAD+ more efficiently than NR in some tissues. Human trials at 250-600 mg daily show improved muscle insulin sensitivity and reduced biological aging markers.
Community Rating
No ratings yet
Compound Profile
NMN (Nicotinamide Mononucleotide)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. NMN (Nicotinamide Mononucleotide) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Elevates intracellular NAD+ in skeletal muscle, liver, and blood, measured at 250-600 mg daily in human RCTs
- Improves insulin sensitivity in prediabetic women at 250 mg daily (Yoshino et al., Cell Metabolism 2021)
- Activates SIRT1/SIRT3 sirtuins, which regulate mitochondrial biogenesis and oxidative stress
- NMN (Nicotinamide Mononucleotide) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Elevates intracellular NAD+ in skeletal muscle, liver, and blood, measured at 250-600 mg daily in human RCTs
- Improves insulin sensitivity in prediabetic women at 250 mg daily (Yoshino et al., Cell Metabolism 2021)
- Activates SIRT1/SIRT3 sirtuins, which regulate mitochondrial biogenesis and oxidative stress
- Reduces biological age markers in a 60-day clinical study at 600 mg/day
In Plain English
Simple summaryNMN (nicotinamide mononucleotide) is a direct precursor to NAD+ -- the nicotinamide adenine dinucleotide that sits at the center of hundreds of metabolic reactions and is required for sirtuins, the family of longevity-associated proteins. NAD+ declines significantly with age: levels in 60-year-olds are roughly half those in 20-year-olds. NMN is one step closer to NAD+ in the biosynthesis pathway than NR (nicotinamide riboside), and a 2023 clinical trial showed NMN supplementation in healthy adults raises blood NAD+ within two weeks. The question of whether raising NAD+ through precursor supplementation translates to meaningful health outcomes in non-deficient humans is the active research question, and the answer isn't yet clear.
- Elevates intracellular NAD+ in skeletal muscle, liver, and blood, measured at 250-600 mg daily in human RCTs
- Improves insulin sensitivity in prediabetic women at 250 mg daily
- Activates SIRT1/SIRT3 sirtuins, which regulate mitochondrial biogenesis and oxidative stress
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is NMN (Nicotinamide Mononucleotide)?
Tap any underlined term for an instant definition.
NMN (Nicotinamide Mononucleotide) is a naturally occurring nucleotide derivative and direct biosynthetic precursor to NAD+ (nicotinamide adenine dinucleotide). It is found in small amounts in foods such as edamame, broccoli, avocado, and tomatoes, and is produced endogenously via the salvage pathway from nicotinamide.
The rationale for NMN supplementation comes from the established decline in NAD+ levels with aging across multiple species including humans, and the critical role NAD+ plays in mitochondrial energy production, DNA damage repair (via PARP enzymes), and sirtuin-mediated regulation of gene expression and cellular metabolism.
Unlike niacin or niacinamide, NMN enters the NAD+ biosynthesis pathway at a point closer to NAD+ itself — it is one enzymatic step away via NMNAT enzymes (NMN → NAD+). This distinguishes it from NR (nicotinamide riboside), which requires two steps (NR → NMN → NAD+).
Key human research milestones include a 2021 Cell Metabolism study (Yoshino et al.) demonstrating that 250 mg/day NMN for 10 weeks improved skeletal muscle insulin signaling and related gene expression in postmenopausal prediabetic women. A 2022 study reported reduced biological age scores over 60 days at 600 mg/day.
Animal studies show even more dramatic results: NMN reverses age-associated physiological decline in mice, restoring vascular function, muscle endurance, bone density, and energy metabolism. Translating these findings to humans remains an active area of research.
NMN works in concert with the entire NAD+ ecosystem — including SIRT1/SIRT3/SIRT5 sirtuins, PARP1/2/3 enzymes, CD38, and the mitochondrial electron transport chain — making it a broad-spectrum research tool for metabolic aging, neurodegeneration, cardiovascular disease, and longevity research.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on NMN (Nicotinamide Mononucleotide). See all Immune System peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Research protocols for NMN typically use 250-1000 mg daily in divided doses or as a single morning dose. Human RCTs have used 250 mg/day (metabolic studies), 500 mg/day (general NAD+ augmentation), and 600 mg/day (aging marker studies).
Standard research dose: 250-500 mg daily Higher studied doses: 600-1250 mg (well tolerated) Timing: Morning, with or without food Duration: Studies range from 4 weeks to 6 months
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
NMN is studied as a sublingual tablet or oral capsule. Some researchers prefer sublingual delivery to bypass first-pass metabolism, though oral bioavailability is well established at doses above 250 mg.
What the research doesn't show
Raising NAD+ in blood is measurable; whether that translates to meaningful benefits in healthy, non-NAD+-deficient adults isn't established. Animal studies are very promising -- NAD+ repletion reverses aging phenotypes in mice -- but mice are not humans and many longevity compounds that worked brilliantly in rodents failed to translate. The human trials to date measure surrogate markers, not hard outcomes like disease prevention or lifespan.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain NMN (Nicotinamide Mononucleotide), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
NMN (Nicotinamide Mononucleotide) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: elevates intracellular nad+ in skeletal muscle, liver, and blood, measured at 250-600 mg daily in human rcts.
The most commonly reported side effect in research subjects is generally well tolerated in clinical trials up to 1250 mg single dose. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
Research Articles
- NMN vs NR: Comparing NAD+ Precursor Bioavailability and Research Evidence8 min read
- NAD+ vs Epithalon: Two Different Approaches to Cellular Aging Research7 min read
How It Compares
NR (nicotinamide riboside) is one metabolic step before NMN in the NAD+ pathway. Both raise NAD+, but whether NMN or NR is 'better' isn't settled -- head-to-head human trials are limited and show comparable blood NAD+ increases at equivalent doses. Niacin (vitamin B3) is the original NAD+ precursor and is cheaper but causes uncomfortable flushing. NAD+ IV infusion bypasses precursor conversion but requires clinical administration.
Compare NMN (Nicotinamide Mononucleotide) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.